Open in new window
|
|
|
Pharmaindustrial News
|
|
Cellipont Bioservices and Adva Biotechnology Unveil ADVA X3 Platform
Cellipont Bioservices has joined hands with Adva Biotechnology, marking the launch of the groundbreaking ADVA X3 platform in North America.
Read more
|
|
|
Avidity Biosciences' Delpacibart Etedesiran Receives FDA Breakthrough Therapy Designation
Despite its severity, there are currently no approved therapies for DM1, making the FDA's recognition of delpacibart etedesiran's potential all the more crucial.
Read more
|
|
|
4C Medical's AltaValve System Granted Breakthrough Device Designation by FDA
The FDA has granted the AltaValve System Breakthrough Device designations for two therapeutic indications.
Read more
|
|
|
BioVersys Extends its Strategic Collaboration with GSK
BioVersys has extended its strategic collaboration with the global biopharma company GSK to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).
Read more
|
|
|
ExcellGene Signs Strategic Partnership with Cytovance Biologics
ExcellGene has forged its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
Read more
|
|
|
Lindus Health Appoints Dr. Tim Garnett to their Advisory Board
Dr. Garnett is a board member of leading biotechs like Maplight Therapeutics and Ophirex, Inc., as well as an advisor to Ukko and Biolojic Design.
Read more
|
|
|
Anixa Biosciences Signs JDA with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types
The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine.
Read more
|
|
|
Grand River Aseptic Manufacturing Opens New Syringe and Cartridge Filling Center
Grand River Aseptic Manufacturing has launched its third world-class facility in five years.
Read more
|
|
Interviews
|
|
Phloton: Revolutionizing Last-Mile Immunization and Diagnostics Delivery
Q: Could you please provide an overview of Enhanced Innovations Pvt. Ltd?
Ankita Mittal: Enhanced Innovations is an innovation development and translation...
Read more
|
|
|
|
This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.
Unsubscribe
|